PDCD1 and bone cancer: However, it is important to note that in a metastatic bone cancer model, despite a temporary increase in pain sensitivity after each treatment, anti-PD-1 immunotherapy leads to long-term advantages by preventing bone destruction and relieving bone cancer pain through the suppression of osteoclastogenesis (144).